Education
About Us
Working with TipRanks
Follow Us
Harrow Health Inc (HROW)
NASDAQ:HROW
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.01Last Year’s EPS
-0.18Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 29.97%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Positive
Harrow demonstrated strong revenue growth and cash flow, along with successful strategic initiatives in product launches and market access. However, the quarter was marred by seasonal revenue weakness and significant one-time expenses. The company's outlook remains positive with expectations for growth in the remainder of the year.Company Guidance
During Harrow's First Quarter 2025 Earnings Conference Call, the company provided guidance indicating a strong outlook for the remainder of the year. They aim to achieve their 2025 revenue target of over $280 million, requiring approximately $232 million in revenue across the next three quarters. In Q1 2025, Harrow's revenue grew by 38% year-over-year, with standout performance from VEVYE, which saw a 35% sequential revenue increase to $21.5 million. Harrow anticipates VEVYE will generate at least $100 million in revenue by year-end. IHEEZO is expected to deliver over $50 million, and the specialty branded products, including TRIESENCE, are projected to contribute at least $50 million. The ImprimisRx compounding business is on track to deliver more than $80 million. Harrow also reported a record $19.7 million in cash flow from operations in Q1 and discussed strategic initiatives such as the VEVYE Access for All program, which has quadrupled new prescriptions and prescribers within seven weeks of launch.Significant Revenue Growth
Harrow reported a 38% year-over-year revenue growth in the first quarter of 2025.
Record Cash Flow
The company delivered a record $19.7 million in cash flow from operations.
VEVYE Revenue Increase
VEVYE revenue rose 35% sequentially, from $16 million in Q4 2024 to $21.5 million in Q1 2025.
Successful Launch of VEVYE Access for All Program
Post-launch, both new prescriptions and weekly VEVYE prescribers at PhilRx quadrupled.
Infrastructure Expansion
The VEVYE team has grown to over 80 sales and marketing professionals, with additional expansion in other teams.
Positive Market Response for TRIESENCE
Market access initiatives for TRIESENCE are expected to unlock about 40% of the overall market, showing significant sales momentum.
Strong ImprimisRx Performance
April appears to be a record month for ImprimisRx, indicating consistent performance.
HROW Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HROW Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $23.59 | $24.40 | +3.43% |
Mar 27, 2025 | $27.87 | $26.21 | -5.96% |
Nov 13, 2024 | $51.80 | $42.86 | -17.26% |
Aug 07, 2024 | $21.98 | $33.92 | +54.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Harrow Health Inc (HROW) report earnings?
Harrow Health Inc (HROW) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Harrow Health Inc (HROW) earnings time?
Harrow Health Inc (HROW) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HROW EPS forecast?
HROW EPS forecast for the fiscal quarter 2025 (Q2) is 0.01.
